Access to PrEP is uneven and problematic, and not just in the U.S.
FDA approves Descovy for PrEP; Delstrigo and Pifeltro approved for switch treatment; Bictegravir, dolutegravir and Tybost for children; and more.
Based on new data, the World Health Organization (WHO) recommended dolutegravir as a preferred HIV drug for all populations living with HIV, including pregnant women and those wanting to conceive.
And other conference highlights including new long-acting drug GS-6207; PrEP on demand; HIV treatment = prevention.
Building blocks for a healthy life, with insights from a nurse educator
Public-private partnerships for a vaccine sustain a global response to help end HIV
Biktarvy and antacids. Descovy FDA hearing. Updated guidelines for transgender individuals. Biktarvy and kids. PrEP4Love. Michael Johnson freed.
Monthly injectable HIV med on the way; HIV pharma sued over pricing practices; Australian PrEP advocate talks about his new HIV status; tenofovir class action lawsuits
After more than 30 years of treating young people living with HIV, Dr. Lisa Henry-Reid reflects on what more still needs to be done
Innovations in prevention and care can be found anywhere—the author highlights three examples
Why Safe Consumption Spaces for people who use drugs would benefit society.
People on treatment with an undetectable viral load do not transmit HIV—here's how.
Anti-alcohol drug, gay journalist grant, life insurance for people with HIV, Grindr & PrEP
With the help of PrEP, Shannon Weber helps positive people have a baby—safely
Insurance coverage and other access hurdles can be overcome, but it might take work